Tags

Type your tag names separated by a space and hit enter

Biomarkers in Huntington's and Parkinson's Disease.
Ann N Y Acad Sci. 2009 Oct; 1180:97-110.AN

Abstract

Parkinson's (PD) and Huntington's disease (HD) are chronic neurodegenerative conditions of the brain with a variety of clinical presentations including a disorder of movement and a range of nonmotor deficits. HD is genetic in origin and the causative gene and protein known, namely mutant Huntingtin, which leads to widespread early neuronal dysfunction and death throughout the brain. In contrast, the etiology of sporadic PD is unknown, and the pathology targets the nigrostriatal dopaminergic neurons with the formation of alpha-synuclein positive Lewy bodies. In both diseases, the ability to accurately diagnose the disease in the early stages and monitor progression over time remains a major challenge given the majority of the pathology is sited deep within the CNS. This challenge has gained extra significance as the development of disease-modifying drugs starts to emerge into the clinic. To this end, there is a need to find biomarkers that will help in the accurate diagnosis of the disease and/or prediction of its clinical onset as well as biomarkers that are able to faithfully track disease progression independent of any symptomatic effects of any therapies. In addition, these same markers may also help stratify each of these heterogeneous disorders into specific subtypes that share particular clinical and pathological characteristics.

Authors+Show Affiliations

Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge CB2 0PY, United Kingdom. go215@cam.ac.ukNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19906264

Citation

O'Keeffe, Gráinne C., et al. "Biomarkers in Huntington's and Parkinson's Disease." Annals of the New York Academy of Sciences, vol. 1180, 2009, pp. 97-110.
O'Keeffe GC, Michell AW, Barker RA. Biomarkers in Huntington's and Parkinson's Disease. Ann N Y Acad Sci. 2009;1180:97-110.
O'Keeffe, G. C., Michell, A. W., & Barker, R. A. (2009). Biomarkers in Huntington's and Parkinson's Disease. Annals of the New York Academy of Sciences, 1180, 97-110. https://doi.org/10.1111/j.1749-6632.2009.04943.x
O'Keeffe GC, Michell AW, Barker RA. Biomarkers in Huntington's and Parkinson's Disease. Ann N Y Acad Sci. 2009;1180:97-110. PubMed PMID: 19906264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biomarkers in Huntington's and Parkinson's Disease. AU - O'Keeffe,Gráinne C, AU - Michell,Andrew W, AU - Barker,Roger A, PY - 2009/11/13/entrez PY - 2009/11/13/pubmed PY - 2009/12/16/medline SP - 97 EP - 110 JF - Annals of the New York Academy of Sciences JO - Ann N Y Acad Sci VL - 1180 N2 - Parkinson's (PD) and Huntington's disease (HD) are chronic neurodegenerative conditions of the brain with a variety of clinical presentations including a disorder of movement and a range of nonmotor deficits. HD is genetic in origin and the causative gene and protein known, namely mutant Huntingtin, which leads to widespread early neuronal dysfunction and death throughout the brain. In contrast, the etiology of sporadic PD is unknown, and the pathology targets the nigrostriatal dopaminergic neurons with the formation of alpha-synuclein positive Lewy bodies. In both diseases, the ability to accurately diagnose the disease in the early stages and monitor progression over time remains a major challenge given the majority of the pathology is sited deep within the CNS. This challenge has gained extra significance as the development of disease-modifying drugs starts to emerge into the clinic. To this end, there is a need to find biomarkers that will help in the accurate diagnosis of the disease and/or prediction of its clinical onset as well as biomarkers that are able to faithfully track disease progression independent of any symptomatic effects of any therapies. In addition, these same markers may also help stratify each of these heterogeneous disorders into specific subtypes that share particular clinical and pathological characteristics. SN - 1749-6632 UR - https://www.unboundmedicine.com/medline/citation/19906264/Biomarkers_in_Huntington's_and_Parkinson's_Disease_ L2 - https://doi.org/10.1111/j.1749-6632.2009.04943.x DB - PRIME DP - Unbound Medicine ER -